Medscape2d
New Trial Seeks to Pin Down Pediatric PAH Treatment
PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...
Medpage Today on MSN11d
Have the New Pulmonary Hypertension Drugs Changed the Game?
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this ...
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)Kiel, Germany, January 8, 2025 – tiakis ...
The American Journal of Managed Care5d
High Uric Acid Appears to Have Causal Role in PAH
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...
Pharmaceutical Technology3d
Cibotercept by Keros Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval
Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.
Merck wins UK approval for lung disease drug acquired in $11 billion deal
UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's therapy to treat a rare lung ...